Medical treatment for diabetic acute kidney disease from 2012 to 2024: advances, prescription trends, and future directions
Kidney Research and Clinical Practice · 01.05.2026 · 45 (3) · 327-342
DOI: 10.23876/j.krcp.25.126 ↗Kurz gefasst
Fachartikel in der Zeitschrift Kidney Research and Clinical Practice, erschienen am 01.05.2026. Verfasst von Heng-Chih Pan und 3 weiteren Autor:innen. Beteiligte Einrichtung: Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Ministry of Science and Technology of Taiwan, National Science and Technology Council Taiwan, National Taiwan University Hospital.
Abstract (Originalsprache)
Diabetic acute kidney disease (AKD) represents a pivotal transitional phase between acute kidney injury (AKI) and chronic kidney disease (CKD), carrying a high risk of progression to end-stage kidney disease. Effective medical management is crucial during this phase. Renin-angiotensin-aldosterone system inhibitors remain the foundation of therapy, and newer agents have expanded the armamentarium. Sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists have been shown to confer significant nephroprotective and cardioprotective effects, including decreased risks of AKD progression, heart failure, and mortality. Finerenone, a novel nonsteroidal mineralocorticoid receptor antagonist, has also been shown to reduce kidney disease progression and cardiovascular events in patients with established diabetic CKD, although its role in AKD remains uncertain. However, real-world data indicate the suboptimal utilization of these therapies, highlighting barriers related to clinical inertia, safety concerns after AKI, and socioeconomic disparities. Future strategies should emphasize the timely initiation and combination of treatments to maximize renoprotection, while exploring emerging agents such as endothelin receptor antagonists and aldosterone synthase inhibitors. Integrating evidence-based therapies, improving adherence to guideline-directed care, and leveraging real-world data to inform clinical practice are necessary to optimize kidney and cardiovascular outcomes in patients with diabetic AKD.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan.
- Department of Medicine, Chang Gung University College of Medicine, Taoyuan, Taiwan.
- Division of Nephrology, Department of Internal Medicine, Keelung Chang Gung Memorial Hospital, Keelung, Taiwan.
- Community Medicine Research Center, Keelung Chang Gung Memorial Hospital, Keelung, Taiwan.
- Division of Nephrology, Department of Internal Medicine, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan.
- Department of Internal Medicine, Far Eastern Memorial Hospital, New Taipei City, Taiwan.
Förderung
- Ministry of Science and Technology of Taiwan
- National Science and Technology Council Taiwan
- National Taiwan University Hospital
- Ministry of Health and Welfare
- National Health Research Institutes
- Mrs. Hsiu-Chin Lee Kidney Research Fund
Zitieren
APA
Pan, H. C., Wang, C. A., Chen, J. Y., & Wu, V. C. (2026). Medical treatment for diabetic acute kidney disease from 2012 to 2024: advances, prescription trends, and future directions. Kidney Research and Clinical Practice, 45(3), 327-342. https://doi.org/10.23876/j.krcp.25.126
Vancouver
Pan HC, Wang CA, Chen JY, Wu VC. Medical treatment for diabetic acute kidney disease from 2012 to 2024: advances, prescription trends, and future directions. Kidney Research and Clinical Practice. 2026;45(3):327-342. doi:10.23876/j.krcp.25.126
BibTeX
@article{Pan2026,
author = {Pan, Heng-Chih and Wang, Chung-An and Chen, Jui-Yi and Wu, Vin-Cent},
title = {Medical treatment for diabetic acute kidney disease from 2012 to 2024: advances, prescription trends, and future directions},
journal = {Kidney Research and Clinical Practice},
year = {2026},
volume = {45},
number = {3},
pages = {327--342},
doi = {10.23876/j.krcp.25.126}
}
EUVIMED